INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE)

Dec 18, 2018 04:36 pm

Law Offices of Howard G. Smith announces an investigation on behalf of Bluebird Bio, Inc. investors (“Bluebird” or the “Company”) (NASDAQ: BLUE) concerning the Company and its officers’ possible violations of federal securities laws.

On December 1, 2018, Bluebird issued a press release informing investors that it had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” Then on December 3, 2018, Seeking Alpha published an article asserting that “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” On this news, shares of Bluebird stock price fell $6.39 per share, or 5.2%, to close at $116.50 on December 3, 2018, thereby injuring investors.

If you purchased Bluebird securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to, or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire